CILA THERAPEUTIC INC.

Biotech · Private

Inhaled dry-powder microsphere mucolytic platform (CIL-0X) that disrupts airway mucus to enhance RNA-LNP transfection efficiency in lungs

Grants
$380K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells$379,948
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1974UBIQUITX, INC.——
1975ACCUNOVO BIOTECHNOLOGIES INC——
1976VLP THERAPEUTICS, INC.——
1977CILA THERAPEUTIC INC.——
1978Liberation Technology Services, Inc.—$25K
1979GORDIAN BIOTECHNOLOGY, INC.——
1980ARCATO LABORATORIES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 6
  • Inhalable Therapeutic Agentsapplication
  • Anti-viral Therapeutic Agents And Uses Thereofapplication
  • Anti-viral Therapeutic Agents And Uses Thereofapplication
  • Inhalable Therapeutic Agentsapplication
  • Inhalable Therapeutic Agentapplication
  • Inhalable Therapeutic Agentapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.